---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011706"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:56:04.595121+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intelligent Bio Solutions preliminary Q4 revenue up ~16% sequentially and YoY, driven by cartridge sales

## Summary
- Preliminary Q4 FY2025 revenue growth of ~16% sequentially and year-over-year, driven by higher-margin cartridge sales and account growth.
- Submitted FDA 510(k) application for opiate test system (codeine) to support planned U.S. market entry.
- Completed multilingual system upgrades and launched localized websites to strengthen global adoption across Europe, Middle East, and Latin America.
- Full-year FY2025 results and Form 10-K expected to be filed during the week of August 11, 2025.

## SEC filing metadata
- accession: 0001493152-25-011706
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315225011706/0001493152-25-011706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315225011706/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011706
- JSON: https://secwatch.observer/filing/0001493152-25-011706.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.